-
Report: Gilead Sciences And Cancer Treatment Company Immunomedics In $20B Deal
Saturday, September 12, 2020 - 6:22pm | 178Read More...Gilead Sciences Inc. (NASDAQ: GILD) is gearing up to purchase drug innovator Immunomedics Inc. (NASDAQ: IMMU) for a price tag exceeding $20 billion. Per the Wall Street Journal, Immunomedics — a biotech known for breast-cancer treatment Trodelvy — was initially a...
-
Immunomedics Announces Encouraging Preclinical Study Data, Shares Give Up Early Morning Gains
Monday, April 18, 2016 - 1:03pm | 239Read More...Immunomedics, Inc. (NASDAQ: IMMU), a clinical stage biopharmaceutical company that focuses on the treatment of cancer, presented data at the 2016 American Association for Cancer Research's annual meeting. Immunomedics said in a corresponding press release that its presentation focused on...
-
Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)
Wednesday, October 3, 2012 - 2:57pm | 549Read More...Here is a quick look at three top-performing biotech stocks, each with a consensus recommendation (among analysts) of Strong Buy. They are Ariad Pharmaceuticals (NASDAQ: ARIA), Merrimack Pharmaceuticals (NASDAQ: MACK) and Synageva BioPharma (NASDAQ: GEVA). Ariad Pharmaceuticals Shares of this...
